Huberman Lab

Huberman Lab ·Dr. Chris Thompson, chief of interventional gastroenterology at Mass General Brigham, joins Andrew Huberman for a wide-ranging tour of gut health and obesity medicine. The episode opens with a walkthrough of the digestive tract organ by organ, the roles of fiber, fermented foods, and the microbiome, and a history of ulcer science from Barry Marshall's H. pylori self-experiment to Otzi the iceman. It then turns to GLP-1 drugs: Thompson welcomes them as the first real answer to obesity's metabolic consequences but documents their limits - adherence collapse within a year, muscle loss that worsens body composition when patients cycle on and off, and super-physiologic dosing whose long-term effects are unknown. The middle of the conversation reconstructs how bariatric surgery actually works. The jejunoileal bypass disaster, Mason's gastric bypass, bands, and the sleeve were all designed around restriction or malabsorption yet operate through gut-hormone mechanisms - a realization traced through Thompson's own 2003 fistula-closure surprise, foregut-exclusion rat experiments, and incretin science running from 1930s London to the Gila-monster venom discovery. That mechanistic understanding now powers endoscopic therapies: his ESG procedure, fundal ghrelin ablation, magnetic anastomosis, and duodenal ablation, each targeting a specific lever, with obesity phenotyping and combination with low-dose drugs on the horizon. A long stretch covers early metabolic screening - the dysregulation sequence from calorie excess to metabolic inflexibility, catchable years before A1C rises with CGMs and fasting insulin - alongside evidence that increased gut permeability is real: organoid, tracer, and LPS-infusion studies. The episode closes with technology and the frontier: surgical AI that coaches procedures in research centers, robotics that compress trainee learning curves, objective surgeon metrics via Everself and AI grading, and a GLP-1 gene therapy delivered to the pancreas tail that has just entered clinical trials in the Netherlands. Thompson's through-line is mechanical: fix underlying problems rather than manage decline, use the least intervention that works, and combine levers instead of maximizing one.